Clinical Trial

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet transfusion refractoriness (PTR) and relapsed or refractory immune thrombocytopenia (ITP). Patients will receive RN1201 cells infusion following lymphodepletion. The study will assess safety, response rates, B-cell depletion, and immune reconstitution. Exploratory analyses will examine in vivo persistence and activity of RN1201.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2026-06-10
Trial Details
NCT Number NCT07072247
Lead Sponsor The First Affiliated Hospital of Soochow University
Collaborators: Allorunning Therapeutics
Conditions Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
Enrollment 9 participants
Start Date 2025-07-07
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-12